GlassScriptPhysician profile
Richard Riley Binks
NPI 1962085506
$2,845.82
in general payments reported to CMS, 2019-2025
24 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $255 · 2023: $457 · 2024: $809 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,591.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $881.42 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $511.96 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $230.27 | 2023-2025 | |
| Amgen INC. | $165.19 | 2022-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $146.61 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Corium, LLC | $123.00 | 2023 | Azstarys |
| Medtronic, INC. | $115.89 | 2023-2025 | Venaseal |
| Novo Nordisk INC | $91.31 | 2023-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $82.87 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Hydrocision, INC. | $77.00 | 2025 | Tenjet |
| Glaxosmithkline, LLC. | $64.03 | 2024 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $45.83 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $42.75 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $34.74 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.70 | 2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.09 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $30.78 | 2022-2023 | |
| Biomarin Pharmaceutical INC. | $24.16 | 2024 | Voxzogo 1.2mg |
| Astellas Pharma US INC | $20.47 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.00 | 2024 | |
| Lundbeck LLC | $18.84 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $17.08 | 2025 | Unithroid |
| Idorsia Pharmaceuticals US INC | $16.65 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $16.18 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Binks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.